Lichen Planus After Denosumab
Osteologie · 01.02.2023 · 32 (01) · 59-60
DOI: 10.1055/a-1970-3166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteologie, erschienen am 01.02.2023. Verfasst von Jakob Höppner und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Lichenoid reactions have been described as a side effect of several drugs. Here we describe the development of lichen planus (LP) of the mammilla following off-label use of denosumab in an adolescent patient with mono-ostotic fibrous dysplasia. Lichen planus is considered an autoimmune disorder. Since receptor activator of nuclear factor κΒ ligand (RANKL), the target of denosumab action, has regulatory function in the immune system, it is feasible, that LP may be caused as part of an immunological dysregulation.
Zitieren
APA
Höppner, J., Susok, L., Gambichler, T., & Grasemann, C. (2023). Lichen Planus After Denosumab. Osteologie, 32(01), 59-60. https://doi.org/10.1055/a-1970-3166
Vancouver
Höppner J, Susok L, Gambichler T, Grasemann C. Lichen Planus After Denosumab. Osteologie. 2023;32(01):59-60. doi:10.1055/a-1970-3166
BibTeX
@article{Hppner2023,
author = {Höppner, Jakob and Susok, Laura and Gambichler, Thilo and Grasemann, Corinna},
title = {Lichen Planus After Denosumab},
journal = {Osteologie},
year = {2023},
volume = {32},
number = {01},
pages = {59--60},
doi = {10.1055/a-1970-3166}
}
EUVIMED